List of Excipients in Branded Drug ENSTILAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
LEO Pharma Inc	ENSTILAR	calcipotriene and betamethasone dipropionate	50222-302	.ALPHA.-TOCOPHEROL, DL-
LEO Pharma Inc	ENSTILAR	calcipotriene and betamethasone dipropionate	50222-302	BUTANE
LEO Pharma Inc	ENSTILAR	calcipotriene and betamethasone dipropionate	50222-302	BUTYLATED HYDROXYTOLUENE
LEO Pharma Inc	ENSTILAR	calcipotriene and betamethasone dipropionate	50222-302	DIMETHYL ETHER
LEO Pharma Inc	ENSTILAR	calcipotriene and betamethasone dipropionate	50222-302	MINERAL OIL

ENSTILAR Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Enstilar is a calcipotriene and betamethasone dipropionate aerosol foam for topical plaque psoriasis. Its commercial differentiation depends heavily on the vehicle: the product combines a lipophilic emollient system, surfactant, hydrocarbon and ether propellants, and a pressurized package to deliver two poorly compatible active ingredients in a cosmetically acceptable foam. The strongest opportunities are generic or follow-on foam products, propellant and packaging reformulation, improved skin feel, lower-cost excipient sourcing, and lifecycle extensions that preserve the vehicle’s delivery advantages.[1]

What is Enstilar and which excipients does it contain?

Enstilar contains calcipotriene 0.005% and betamethasone dipropionate 0.064% in an aerosol foam. It is approved for topical treatment of plaque psoriasis in patients aged 12 years and older. The labeled inactive ingredients are butylated hydroxytoluene, mineral oil, polyoxypropylene stearyl ether, white petrolatum, butane, and dimethyl ether.[1]

Component	Role in the formulation	Commercial relevance
Mineral oil	Lipophilic emollient and solvent phase	Supports skin feel and active dispersion
White petrolatum	Occlusive emollient	Improves moisturization and residence on skin
Polyoxypropylene stearyl ether	Surfactant and foam stabilizer	Helps form and maintain the aerosol foam
Butylated hydroxytoluene	Antioxidant	Protects oxidation-sensitive components
Butane	Volatile propellant	Provides expansion and spray force
Dimethyl ether	Propellant and solvent	Contributes to atomization and foam structure

The formulation uses no water-based phase in the labeled composition. That design reduces hydrolytic-risk exposure and supports incorporation of lipophilic ingredients, but it creates specific challenges in aerosol performance, flammability, packaging compatibility, and patient perception.

How does the Enstilar excipient system create product differentiation?

The principal differentiator is the foam vehicle rather than the active ingredients. Calcipotriene and betamethasone dipropionate are both established compounds used in psoriasis products, including ointments, gels, suspensions, and creams. Enstilar’s value proposition is the delivery system.

The vehicle provides four technical advantages:

1. It distributes the active ingredients across the skin without the heavy spread profile associated with conventional petrolatum ointments.
2. It delivers an anhydrous environment that can support chemical stability.
3. It provides rapid evaporation and collapse of the foam after application.
4. It uses a pressurized package that can meter a relatively small quantity onto affected areas.

The excipient strategy also addresses adherence. Patients often reject greasy topical products, particularly on the scalp, trunk, and intertriginous areas. A foam that spreads quickly and leaves less visible residue can improve practical usability even when the active ingredients are familiar.

The tradeoff is that the same propellant system creates manufacturing and distribution constraints. The product is flammable, requires pressure-rated packaging, and may be more expensive to fill and ship than a conventional tube-based cream.

What formulation patents protect Enstilar’s foam technology?

Enstilar’s protection has historically centered on the combination of calcipotriene and betamethasone dipropionate in a foamable topical composition, including the vehicle architecture and delivery format. Patent scope can include:

• The active-ingredient combination.
• Defined concentrations of calcipotriene and betamethasone dipropionate.
• Anhydrous or substantially nonaqueous vehicles.
• Foamable compositions containing emollients and surfactants.
• Propellant systems.
• Physical stability and active uniformity.
• Use of the composition for psoriasis treatment.

The key U.S. patent commonly associated with the calcipotriene/betamethasone foam platform is U.S. Patent No. 8,501,737. Patent term, pediatric extensions, terminal disclaimers, and Orange Book listing status must be evaluated against the current U.S. Patent and Trademark Office and FDA records rather than inferred from the grant date.[2,3]

Protection category	Relevance to an Enstilar follow-on
Active combination	May create formulation and method-of-use barriers
Foam vehicle	Can constrain direct copies using the same excipient architecture
Propellant system	May affect design-around options
Manufacturing process	Can create non-obviousness risk even where composition differs
Method of treatment	May remain relevant to labeling and Paragraph IV strategy
Container closure	May affect equivalence, stability, and device performance

For an ANDA applicant, the practical question is not only whether the active ingredients are off patent. The applicant must determine whether the proposed product infringes any unexpired listed patents and whether it can demonstrate pharmaceutical equivalence, bioequivalence, and equivalent performance.

When does Enstilar lose exclusivity?

Enstilar received FDA approval in 2015.[1] FDA exclusivity and patent exclusivity are separate. Regulatory exclusivity may expire before all patent barriers, while a patent may remain enforceable after the end of FDA-granted exclusivity.

Milestone	Significance
2015 FDA approval	Established the reference product for U.S. generic development
New chemical entity exclusivity	Not the main barrier because both active ingredients were previously known
Formulation and method patents	Potentially more important than NCE exclusivity
Orange Book-listed patents	Determine Paragraph IV and certification requirements
Pediatric exclusivity	Can add six months if applicable and properly attached to eligible patents
Generic approval	Depends on patent certifications, litigation, and ANDA review

A generic applicant can file an ANDA before patent expiration using a Paragraph IV certification. If the patent holder sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments.[3,4]

What generic entry risks exist for Enstilar?

Generic entry risk is meaningful because the active ingredients are established and the dosage form is commercially validated. The technical barrier is higher than for a standard cream or ointment because a generic applicant must reproduce or adequately match aerosol foam performance.

The principal risks are:

• Failure to match active uniformity during canister discharge.
• Different foam density or collapse time.
• Inconsistent dose delivery near the end of canister life.
• Divergent droplet or particle-size distribution.
• Chemical interaction between propellants and the formulation.
• Leakage, valve malfunction, or pressure loss.
• Differences in skin residue, spreadability, and drying.
• Inability to demonstrate equivalent performance under the applicable FDA pathway.

A direct Q1/Q2 excipient match may reduce formulation risk but can increase patent exposure and dependence on the incumbent’s supply chain. A design-around using a different surfactant, hydrocarbon blend, or propellant may reduce literal infringement risk but raise equivalence and product-performance risk.

How can an ANDA or 505(b)(2) applicant design around the Enstilar formulation?

The strongest design-around strategies alter one or more non-active components while retaining the same active concentrations and topical indication.

Propellant redesign

Potential approaches include:

• Replacing or reducing dimethyl ether.
• Using a different hydrocarbon propellant ratio.
• Adopting a lower-flammability or nonflammable propellant system.
• Developing a bag-on-valve package that separates the formulation from the propellant.
• Using compressed air or nitrogen in a mechanically foamed system.

A propellant change can affect foam texture, spray pattern, evaporation, active solubility, and canister pressure. It also changes transportation, warehouse, and pharmacy handling requirements.

Emollient redesign

Mineral oil and white petrolatum are cost-effective and well understood, but they can produce an oily after-feel. Alternatives may include:

• Isopropyl myristate.
• Medium-chain triglycerides.
• Hydrogenated polyisobutene.
• Dimethicone.
• Synthetic hydrocarbons.
• Ester-based emollients.

The commercial objective is to improve spreadability and reduce residue without compromising active solubility or foam collapse.

Surfactant redesign

Polyoxypropylene stearyl ether is a central technical excipient. Substitution with another nonionic surfactant could create a patent design-around, but surfactant changes may alter:

• Foam stability.
• Active partitioning.
• Skin irritation.
• Valve compatibility.
• Homogeneity during storage.
• Deposition on the skin.

A new surfactant system may support a differentiated product but increases development and regulatory comparability risk.

Water-containing systems

A water-based foam could improve skin feel and reduce reliance on hydrocarbon solvents. It would also introduce additional risks:

• Calcipotriene stability.
• Betamethasone degradation.
• Microbial control.
• Preservative selection.
• pH control.
• Emulsion stability.
• Container corrosion.

A water-containing product may be better suited to a 505(b)(2) strategy than a conventional ANDA if the formulation differs materially from the reference product.

What excipient opportunities exist for Enstilar competitors?

Low-cost generic excipients

The largest near-term opportunity is procurement optimization. Mineral oil, petrolatum, butane, and dimethyl ether are commodity or widely available materials. Commercial advantage can come from:

• Dual sourcing.
• Regional propellant supply.
• Lower-cost pharmaceutical-grade hydrocarbons.
• Contract aerosol filling.
• Reduced canister and valve costs.
• Improved fill-weight control.

The main constraint is that excipient savings may be small compared with the cost of aerosol manufacturing, quality testing, litigation, and market access.

Improved cosmetic profile

A “less greasy” foam is commercially attractive. A competitor could use a lighter emollient system while retaining equivalent active delivery. This opportunity is strongest in patients treating visible areas or large body-surface regions.

Relevant product attributes include:

• Faster disappearance after application.
• Lower oily residue.
• Less transfer to clothing.
• Easier scalp application.
• Better compatibility with daily moisturizers.
• Lower odor.
• Lower post-application cooling or irritation.

These attributes can support a prescription product, an authorized generic, or a line extension where patent and regulatory strategy permits.

Propellant and sustainability positioning

Propellant selection creates an opportunity for lower-emission or lower-flammability products. A bag-on-valve system can separate the formulation from the propellant and may support broader packaging options. A mechanically generated foam could reduce volatile-organic-compound use.

The commercial risk is that a nontraditional package may feel different to patients and may require new human-factors, device, stability, and performance evidence.

Multidose and metered-dose packaging

Improved valves and actuators can address dose consistency and waste. Opportunities include:

• Metered-dose delivery.
• Smaller travel-size canisters.
• Improved scalp actuators.
• More precise application to plaques.
• Reduced residual product in the package.

Packaging changes may create device or combination-product considerations even when the active formulation remains unchanged.

What manufacturing and intellectual-property barriers affect Enstilar competitors?

A successful product requires more than matching the labeled excipients. Aerosol foam manufacturing involves controlled filling, pressure testing, valve crimping, leak testing, microbial and chemical stability assessment, and evaluation of the product throughout canister life.

Key manufacturing barriers include:

Barrier	Business impact
Propellant handling	Requires specialized facilities and safety controls
Valve and actuator sourcing	Creates dependence on qualified component suppliers
Active uniformity	Can be difficult in a low-volume, lipophilic system
Fill-weight control	Directly affects dose delivery and economics
Canister compatibility	May affect stability, corrosion, and leakage
Foam reproducibility	Influences clinical usability and approval risk
Scale-up	Small laboratory batches may not predict commercial performance

The most defensible intellectual property generally covers a narrow formulation window that links excipient selection to a measurable performance outcome, such as stability, foam quality, active uniformity, or skin deposition. Broad claims directed only to known active ingredients and ordinary topical excipients face greater validity and design-around pressure.

What is the FDA regulatory status of Enstilar?

Enstilar is an FDA-approved prescription topical aerosol foam.[1] It is not a biologic and therefore does not create biosimilar exposure. Competitive products would generally follow an ANDA pathway if they can establish pharmaceutical equivalence and bioequivalence to the reference product. A materially different vehicle, package, strength, indication, or delivery mechanism may require a 505(b)(2) application.

The regulatory strategy turns on how closely the proposed product matches:

• Active ingredients and strengths.
• Dosage form.
• Route of administration.
• Inactive ingredients.
• Device and container closure.
• Delivered dose.
• Product performance.
• Labeling.

The FDA’s product-specific guidance and current Orange Book listing are controlling for an applicant’s development and certification strategy.[3,5]

What is the commercial outlook for Enstilar excipient innovation?

Enstilar’s commercial opportunity is strongest in markets where topical adherence and cosmetic acceptability influence treatment persistence. The product competes with calcipotriene/betamethasone ointments, creams, gels, suspensions, and nonsteroidal topical psoriasis treatments.

Opportunity	Market logic	Development risk
Direct generic foam	Retains recognized dosage form	Patent and equivalence risk
Authorized generic	Uses established formulation and brand know-how	Lower differentiation
Non-greasy reformulation	Improves patient usability	May require 505(b)(2)
Propellant-reduced foam	Addresses safety and sustainability concerns	Performance and packaging risk
Scalp-specific actuator	Improves application precision	Device and usability work
Lower-cost international product	Expands access in price-sensitive markets	Regional regulatory and supply issues
Combination with regimen-support packaging	Improves adherence	Limited IP protection unless technically novel

Revenue exposure is concentrated in the reference product’s branded topical psoriasis franchise and in any generic launch that captures formularies through lower cost. Because topical psoriasis products are often substitutable at the prescriber and payer level, a generic with comparable foam performance could pressure price rapidly. A visibly inferior cosmetic profile, however, may limit substitution despite active-ingredient equivalence.

How does Enstilar compare with conventional calcipotriene and betamethasone products?

Attribute	Enstilar foam	Ointment	Cream or gel
Active combination	Calcipotriene plus betamethasone dipropionate	May contain one or both actives	May contain one or both actives
Vehicle	Anhydrous aerosol foam	Highly occlusive	Less occlusive
Patient feel	Rapidly spreading, lighter than ointment	Greasier	Usually lighter
Manufacturing	Pressurized aerosol	Tube or jar filling	Tube, pump, or bottle
Patent exposure	Foam and combination claims	Product-specific claims	Product-specific claims
Generic complexity	High	Lower	Moderate
Packaging risk	Canister, valve, propellant	Conventional tube	Conventional package

Key Takeaways

• Enstilar’s commercial differentiation is primarily its aerosol foam vehicle, not the novelty of its active ingredients.
• The labeled excipient system includes mineral oil, white petrolatum, polyoxypropylene stearyl ether, butylated hydroxytoluene, butane, and dimethyl ether.
• The main generic barriers are foam performance, aerosol manufacturing, container-closure compatibility, and formulation patent claims.
• The most credible formulation opportunities are lighter emollients, alternative surfactants, improved actuators, metered-dose delivery, and lower-flammability or lower-emission propellant systems.
• A close formulation may fit an ANDA strategy but create greater patent exposure. A materially different foam may support a 505(b)(2) strategy but require more comparative development.
• Enstilar is a small-molecule topical product. Biosimilar risk does not apply; generic substitution risk does.
• The strongest commercial positioning is a product that matches Enstilar’s active delivery while improving residue, scalp application, dose consistency, packaging, or cost.

FAQs

Can Enstilar’s mineral oil and petrolatum vehicle be replaced?

Yes. Replacement with esters, synthetic hydrocarbons, silicones, or triglycerides is technically possible, but the substitute must preserve active uniformity, foam formation, stability, skin deposition, and patient acceptability.

Is Enstilar an aerosol drug-device combination product?

Its pressurized canister, valve, and actuator are integral to dose delivery. Regulatory treatment depends on the product configuration and FDA determination, but development must address both formulation performance and container-closure functionality.

Does changing the propellant avoid Enstilar patent risk?

Not necessarily. Patent claims may cover the active combination, vehicle, foamable composition, or use method independently of a particular propellant. A propellant change can reduce some infringement risk while creating new equivalence and performance issues.

Is a water-based Enstilar substitute commercially attractive?

It may improve cosmetic feel and reduce hydrocarbon use, but water introduces stability, preservation, pH, emulsion, and active-degradation risks. Such a product may be better suited to a 505(b)(2) pathway than a simple ANDA.

What is the highest-value excipient innovation for an Enstilar competitor?

A lighter, less greasy vehicle with equivalent active delivery has the clearest patient-facing value. A lower-cost aerosol process or improved packaging may deliver greater margin value, but those benefits are less visible and may not support premium pricing.

References

1. U.S. Food and Drug Administration. (2015). Enstilar (calcipotriene and betamethasone dipropionate) aerosol foam prescribing information.
2. United States Patent and Trademark Office. (2013). U.S. Patent No. 8,501,737, pharmaceutical composition comprising calcipotriol and betamethasone dipropionate.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulations and patent certifications.
5. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development.